Review article · 2022 · Open access

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Hager Mohamed, Theodore E. Gurrola, Rachel E. Berman, Mackenzie L. Collins, Ilker Kudret Sariyer, Michael R. Nonnemacher, Brian L. Wigdahl

Frontiers in Immunology, 12, 816515 · Published 20 January 2022 · DOI 10.3389/fimmu.2021.816515

Open PDFView at the publisherCite this paper

In brief

“Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy” is a 2022 review article by Hager Mohamed and 6 co-authors, published in Frontiers in Immunology. OpenAlex counts 94 citations as of 19 November 2026, which puts it in the top 2% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Frontiers in Immunology.

Citations
94
Most cited in
2024 (23)
Field-weighted impact
1.65
References
179
Authors
7

Abstract

Globally, human immunodeficiency virus type 1 (HIV-1) infection is a major health burden for which successful therapeutic options are still being investigated. Challenges facing current drugs that are part of the established life-long antiretroviral therapy (ART) include toxicity, development of drug resistant HIV-1 strains, the cost of treatment, and the inability to eradicate the provirus from infected cells. For these reasons, novel anti-HIV-1 therapeutics that can prevent or eliminate disease progression including the onset of the acquired immunodeficiency syndrome (AIDS) are needed. While development of HIV-1 vaccination has also been challenging, recent advancements demonstrate that infection of HIV-1-susceptible cells can be prevented in individuals living with HIV-1, by targeting C-C chemokine receptor type 5 (CCR5). CCR5 serves many functions in the human immune response and is a co-receptor utilized by HIV-1 for entry into immune cells. Therapeutics targeting CCR5 generally involve gene editing techniques including CRISPR, CCR5 blockade using antibodies or antagonists, or combinations of both. Here we review the efficacy of these approaches and discuss the potential of their use in the clinic as novel ART-independent therapies for HIV-1 infection.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Mohamed, H., Gurrola, T. E., Berman, R. E., Collins, M. L., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. L. (2022). Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Frontiers in Immunology, 12, 816515. https://doi.org/10.3389/fimmu.2021.816515

MLA 9

Mohamed, Hager, et al. “Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.” Frontiers in Immunology, vol. 12, 2022, p. 816515. https://doi.org/10.3389/fimmu.2021.816515.

Chicago

Mohamed, Hager, Theodore E. Gurrola, Rachel E. Berman, Mackenzie L. Collins, Ilker Kudret Sariyer, Michael R. Nonnemacher, and Brian L. Wigdahl. 2022. “Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy.” Frontiers in Immunology 12: 816515. https://doi.org/10.3389/fimmu.2021.816515.

Harvard

Mohamed, H. et al. (2022) ‘Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy’, Frontiers in Immunology, 12, p. 816515. doi:10.3389/fimmu.2021.816515.

IEEE

H. Mohamed et al., “Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy,” Frontiers in Immunology, vol. 12, p. 816515, 2022, doi: 10.3389/fimmu.2021.816515.

BibTeX

@article{mohamed2022targeting,
  title     = {{Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy}},
  author    = {Mohamed, Hager and Gurrola, Theodore E. and Berman, Rachel E. and Collins, Mackenzie L. and Sariyer, Ilker Kudret and Nonnemacher, Michael R. and Wigdahl, Brian L.},
  journal   = {Frontiers in Immunology},
  year      = {2022},
  volume    = {12},
  pages     = {816515},
  doi       = {10.3389/fimmu.2021.816515},
  url       = {https://doi.org/10.3389/fimmu.2021.816515}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202277
20232020
20242323
20252323
20262121

Its field-weighted citation impact is 1.65: it has been cited 1.65 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment

  • HIV-1
  • CCR5
  • CCR5 antagonist
  • CRISPR gene editing
  • HIV-1 drug resistance
  • HIV prevention

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Mohamed, H., Gurrola, T. E., Berman, R. E., Collins, M. L., Sariyer, I. K., Nonnemacher, M. R., & Wigdahl, B. L. (2022). Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy. Frontiers in Immunology, 12, 816515. https://doi.org/10.3389/fimmu.2021.816515

How many times has this paper been cited?

94 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Frontiers in Immunology: sign in and open the PDF from this page.

Who wrote this paper?

Hager Mohamed, Theodore E. Gurrola, Rachel E. Berman, Mackenzie L. Collins, Ilker Kudret Sariyer, Michael R. Nonnemacher, Brian L. Wigdahl.

What is the DOI of this paper?

10.3389/fimmu.2021.816515, permanently at https://doi.org/10.3389/fimmu.2021.816515. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.